Back | Next |
home / stock / rdgl / rdgl message board
Subject | By | Source | When |
---|---|---|---|
The offering hasnt even been approved yet. The | wrinklesobw | investorshub | 07/01/2024 7:39:42 PM |
Does the selling start automatically? | Jimmlu59 | investorshub | 07/01/2024 7:36:04 PM |
Give the people time to look at the | mc73 | investorshub | 07/01/2024 7:28:26 PM |
Thank you. Understood and agreed. I | Tiger Money | investorshub | 07/01/2024 6:53:39 PM |
🚀https://www.clinicaltrialsarena.com/news/vivos-eyes-human-trials-for-ra | den4 | investorshub | 07/01/2024 6:53:38 PM |
Totally | Roofus | investorshub | 07/01/2024 6:47:50 PM |
His posts and arrival on the board are | CatfishHunter | investorshub | 07/01/2024 6:42:45 PM |
And done | Tiger Money | investorshub | 07/01/2024 6:36:34 PM |
Oh yes, I forgot about that. The | Tiger Money | investorshub | 07/01/2024 6:36:13 PM |
I definitely wouldnt take anything he says seriously, | wrinklesobw | investorshub | 07/01/2024 6:34:20 PM |
Not really. They are going to let this | AtlasQ | investorshub | 07/01/2024 6:24:24 PM |
Catfish- do I need to put this guy | Tiger Money | investorshub | 07/01/2024 6:18:24 PM |
Wrong on several fronts. But you already know | CatfishHunter | investorshub | 07/01/2024 6:16:27 PM |
I hear ya and I dont use it | Tiger Money | investorshub | 07/01/2024 6:16:25 PM |
I wish a bigger company would put them | PioneerEmpire67 | investorshub | 07/01/2024 6:15:01 PM |
So far the Submission & Benzinga both backfired. | AtlasQ | investorshub | 07/01/2024 6:02:35 PM |
Benzinga just officially posted on the $RDGL ST board. | Roofus | investorshub | 07/01/2024 5:45:24 PM |
Its not a cure. Its a treatment. | kayak_wench | investorshub | 07/01/2024 5:21:01 PM |
https://www.benzinga.com/partner/biotech/24/07/39574547/vivos-one-step-closer-to | mc73 | investorshub | 07/01/2024 5:19:10 PM |
Thats the difference between swing/traders vs long term | den4 | investorshub | 07/01/2024 4:57:13 PM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...